DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Interim Report
Ad hoc announcement pursuant to Art. 53 of the SIX Listing Rules
BB Biotech AG publishes its interim report
BB Biotech AG (ISIN CH0038389992) today published its interim report as at March 31, 2022, which covers the results of its business activities for the first three months of 2022.
Based on the consolidated accounts of BB Biotech AG, net loss for the period ended March 31, 2022 amounted to CHF 300 mn (profit of CHF 221 mn in the same period 2021). For an investment company, the results reflect the share price development of the companies held in the portfolio.
BB Biotech AG is an investment company with its registered office in Schaffhausen/Switzerland and listed on the Swiss, German and Italian stock exchanges. It has invested in innovative drug developers headquartered primarily in the US and Western Europe. BB Biotech is one of the world's largest investors in this sector. BB Biotech relies on the long-standing experience of its distinguished Board of Directors and the investment research skills of the experienced investment management team of Bellevue Asset Management AG when making its investment decisions.
22-Apr-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Company:||BB BIOTECH AG|
|Phone:||+41 52 624 08 45|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Mailand, SIX|
|EQS News ID:||1331939|
|End of Announcement||DGAP News Service|
1331939 22-Apr-2022 CET/CEST